Citations

Clear

68 citation(s) found for "KC, Madhav".

African Genetic Similarity Is Associated with Reduced Inflammation and Enhanced Adaptive Immunity in Multiple Myeloma
Pilcher, William , Tang, Hongwei, Ferguson, Katherine, Foltz, Steven , Michaud, Marina E. , Satpathy, Sarthak , Shah, Nishi , Jin, Yuxin , Ohlstrom, Denis, Bakhtiari, Mojtaba , Acharya, Chaitanya R. , Gout, Alexander M. , Keats, Jonathan J. , Dhodapkar, Madhav V. , Avigan, David , Vij, Ravi, Kumar, Shaji , Cho, Hearn Jay , Vlachos, Ioannis S. , Ding, Li , Gnjatic, Sacha , Cole, Craig E. , Nooka, Ajay K. , Lonial, Sagar, Carpten, John, Baughn, Linda B. , Bhasin, Manoj

Mayo Clinic

Blood Journal | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033999 | PMID 42832384 Get It

The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Wierda, William G., Brown, Jennifer, Abramson, Jeremy, Bociek, Greg, Boyer, Daniel F. , Cortese, Matthew J , Cripe, Larry D., D’Angelo, Christopher R. , Darnell, Elijah P., Davis, Randall S. , Eradat, Herbert, Esteghamat, Naseem , Fitzgerald, Lindsey , Fletcher, Christopher D., Gaballa, Sameh , Kamdar, Manali, Kipps, Thomas J., Ma, Shuo, Nakhoda, Shazia, Schorr, Andrew, Schuster, Stephen, Seshadri, Madhav, Shanafelt, T., Ujjani, Chaitra, Wagner-Johnston, Nina, Woyach, Jennifer A. , Dwyer, Mary, Sundar, Hema, Shanafelt, Tait D. , Shanafelt, Tait D , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Huntington, Scott F. , Kahl, Brad S. , Kamdar, Manali , Kipps, Thomas J. , Ma, Shuo, Mosse, Claudio A. , Nakhoda, Shazia , Parikh, Sameer A. , Riedell, Peter A. , Seshadri, Madhav , Siddiqi, Tanya , Sitlinger, Andrea Phillips , Thompson, Meghan C , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Dwyer, Mary A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2026 | Volume: 24 | Issue: 3 | Pages: 68-80

10.6004/jnccn.2026.0012 | PMID 41825137 Get It

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.
Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma
Ohlstrom, Denis , Pilcher, William , Michaud, Marina E. , Acharya, Chaitanya R. , Satpathy, Sarthak , Gonzalez‐Kozlova, Edgar , Jayasinghe, Reyka G. , Ferguson, Katherine , Mumme, Hope , Nanda, Shivani , Mantrala, Sowmitri Karthikeya , Karagkouni, Dimitra , Pabustan, Nick , Santos, Junia Vieira Dos , Gout, Alexander M. , Kourelis, Taxiarchis , Vij, Ravi , Dhodapkar, Madhav V. , Avigan, David , Kumar, Shaji , Ding, Li , Gnjatic, Sacha , Ohlstrom, Denis J , Pilcher, William , Acharya, Chaitanya , Mumme, Hope L , Song, Yizhe , Mantrala, Sowmitri , Karagkouni, Dimitra , Schulman, Jessica , Pabustan, Nick , Vieira Dos Santos, Junia , Sherbenou, Daniel W , Keats, Jonathan J , Gout, Alexander M , Foltz, Steven , Lagana, Alessandro , Kourelis, Taxiarchis , Vij, Ravi , Dhodapkar, Madhav V , Avigan, David , Cho, Hearn Jay , Baughn, Linda B , Nooka, Ajay K , Lonial, Sagar , Kumar, Shaji K , Samur, Mehmet K , Vlachos, Ioannis S , Ding, Li , Gnjatic, Sacha , Mulligan, George , Bhasin, Manoj K , Jayasinghe, Reyka G , Song, Yizhe , Keats, Jonathan J. , Cho, Hearn Jay , Baughn, Linda B. , Nooka, Ajay K. , Lonial, Sagar , Samur, Mehmet , Vlachos, Ioannis S. , Mulligan, George

Mayo Clinic

Blood Cancer Discovery | December 9, 2025 | Volume: 7 | Issue: 2 | Pages: 266-286

10.1158/2643-3230.bcd-25-0205 | PMID 41364805 Get It

Abstract Multiple myeloma is a malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment (IME). To investigate immune correlates of treatment response and disease progression, we conducted multi-omics profiling including CD138neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138pos bulk RNA and whole-genome sequencing from 209 samples. In longitudinal analyses, interferon-γ signaling associated with markers of impaired T-cell memory after autologous stem cell transplant, whereas naïve B-cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48; P = 2.3e−4). At disease progression, multiple myeloma cells upregulated cancer–testis antigens (CTAg) and immune effector genes, with concurrent B-cell depletion, enrichment of myeloid-derived suppressor cell expression, and phenotypic T-cell exhaustion. These findings highlight dynamic immune–tumor interactions, identifying naïve B-cell reconstitution as a biomarker of durable response and CTAgs as potential targets for high-risk disease at progression. Significance: Longitudinal profiling of multiple myeloma and the IME revealed dynamic immune–tumor interactions across the disease course. Altered expression in CD8+ T cells limited memory phenotype after transplant, whereas naïve B-cell recovery associated with sustained treatment response. At progression, CTAg expression associated with immunosuppression, revealing novel mechanisms of immune dysregulation.
Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes
Michaud, Marina E. , Ferguson, Katherine , Karagkouni, Dimitra , Network, MMRF Immune Atlas, Kumar, Shaji, Dhodapkar, Madhav V. , Vij, Ravi , Cho, Hearn, Avigan, David, Kourelis, Taxiarchis , Mulligan, George, Pilcher, William , Satpathy, Sarthak , Ohlstrom, Denis , Gonzalez‐Kozlova, Edgar , Acharya, Chaitanya R. , Song, Yizhe , Lagana, Alessandro , Kumar, Shaji , Parekh, Samir , Vlachos, Ioannis S. , Gnjatic, Sacha , Li, Ding , Lonial, Sagar , Nooka, Ajay K. , Bhasin, Manoj K

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2179-2179

10.1182/blood-2025-2179 Get It

Abstract Introduction: Multiple Myeloma (MM) is a complex hematologic malignancy, where patients often display one or more potentially high risk cytogenetic alterations associated with poor outcomes. Traditional high risk cytogenetics events in myeloma, such as NSD2 t(4;14) translocations, gain of 1q21, or deletion of 17p13, have often been studied in isolation, but emerging evidence suggests the combination of these high risk alterations has a greater negative prognostic impact than any on their own. This has been recently reflected in risk stratification guidelines from IMS and IMWG, which consider certain events, such as t(4;14), as high risk only in combination with gain of 1q21 or deletion of 1p32. Still, the mechanisms through which multi-hit high risk events disrupt the microenvironment and promote poor outcomes remains unclear. We hypothesize that myelomas with multiple high risk alterations remodel the immune environment to promote tumor progression and immune escape. Methods: To study the role of multi-hit high risk cytogenetics on the immune microenvironment, we analyzed CD138-bone marrow aspirate single-cell RNA sequencing (scRNAseq) data from 337 newly diagnosed MM patients from the MMRF CoMMpass study, generated as part of the Immune Atlas initiative. Cytogenetic alterations for these patients were derived from whole-genome and whole-exome sequencing of CD138+ bone marrow aspirates from the MMRF CoMMpass cohort. Patients were classified as multi-hit high-risk MM if they exhibited either (i) two high-risk cytogenetic events, including NSD2 t(4;14), MAF t(14;16), del(17p13), or (ii) one high-risk event with gain of 1q21. Results: Based on cytogenetic information, 33 patients in the Immune Atlas cohort were classified as 'multi-hit’ high-risk, while 34 patients had only a single high-risk alteration. These multi-hit high risk patents displayed significantly worse progression free survival compared to standard risk patients, adjusting for age, therapy, and ASCT (HR=2.34, p<7.2e-5), while single-hit patients showed a non-significant trend towards worse outcomes (HR=1.51, p=0.071). The most frequent multi-hit risk event in the cohort was NSD2 t(4;14) in combination with 1q21, observed in 23 patients. Compositional analysis of the immune populations in the scRNAseq data revealed that relative to both standard and single-hit high risk patients, multi-hit high risk patients displayed significant reductions in IFN-I stimulated CD4+ and CD8+ T cell populations, marked by decreased expression for antiviral response markers such as ISG15, XAF1, and IFI44L. Enrichment of inflammatory CD16+ non-classical monocytes was also observed. Further analysis of the most frequent multi-hit risk event, NSD2 with 1q21, revealed distinct enrichment of late-activated cytotoxic HLA+ CD8+T cells and cytotoxic CD4+.T cells. Neither alteration was observed in patients with single-hit NSD2 or 1q21. Further analysis on the interactions between high risk events revealed distinct transcriptomic profiles dependent on the high risk events involved, particularly in multi-hit events involving mutations or deletions of TP53 or gain of 1q21. Reduction in IFN-I signaling across various immune populations was primarily restricted to multi-hit risk events involving gain of 1q21. Conversely, patients with biallelic loss of TP53 displayed significant enrichment of these same IFN-I populations. Given this contrast in IFN-I signaling spanning multiple immune subtypes, we hypothesized that the malignant myeloma cells might similarly display altered IFN-I activity. Utilizing CD138+ myeloma bulk RNA sequencing data from CoMMpass, we found that IFN-I response scores strongly correlated between paired scRNA immune and bulk RNAseq tumor datasets (R2: 0.75, p=1.63e-32). Across 660 patients with bulk RNAseq and cytogenetic data, we confirmed significant reductions in IFN-I response scores in tumor cells in multi-hit high risk involving 1q21, and significant enrichment in those with complete loss of TP53 relative to standard-risk MM. Conclusions: Overall, we do observe that MM patients with multiple high risk cytogenetic alterations display distinct immunologic traits relative to standard risk or single-hit high risk patients in addition to significantly worse outcomes. Furthermore, we find variability in the immune alterations observed based on the cytogenetic events involved, further illustrating the heterogeneity in how MM shapes the immune microenvironment.
IMG-121. BraTS-Pathology 2024: Insights and Future Directions Informed by the AI-RANO & RANO-RGP Effort to Assess Glioblastoma Heterogeneity
Thakur, Siddhesh , Malec, Sylwia , Pitarc, Carla, Linardos, Akis , Innani, Shubham , Adap, Sanyukta, Moassefi, Mana, Nasrallah, MacLean P. , Gubbiotti, Maria A. , López, Giselle Y. , Karargyris, Alexandros , Kassem, Hasan, Miller, Michael L. , Baheti, Bhakti , Zhang, Juexin , Weng, Ying , Kumar, Rithik, Vinit, Vinit, Dhingra, Twinkle, Zahra, Syed Rameem , Sandino, Alvaro, Cooper, Lee , Bell, Robert , Faghani, Shahriar , Moassefi, Mana , Ahrendsen, Jared T. , Barresi, Valeria , Lucas, Calixto‐Hope G. , Chung, Verena , Miller, Michael, Pati, Sarthak , Wodziński, Marek , Müller, Henning , Chen, Ke , Kumar, Rithik, Arora, Madhav, Gupta, Ankur , Tiwari, Pallavi , Huse, Jason T. , Bakas, Spyridon

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v303-v304

10.1093/neuonc/noaf201.1200 Get It

Abstract INTRODUCTION Glioblastoma is the most common malignant adult brain tumor with poor prognosis, largely due to its heterogeneous landscape. The AI-RANO and RANO-RGP groups organized the BraTS-Pathology 2024 challenge, providing a publicly-available dataset and a benchmarking environment for AI models to automatically identify six clinically-relevant histopathologic sub-regions in H&E-stained whole slide images (WSIs). METHODS We reclassified the TCGA-GBM and TCGA-LGG data according to the WHO 2021 criteria and identified diagnostic WSIs of 188 glioblastoma (IDH-wt, CNS WHO Gr.4) patients. A well-defined annotation protocol was communicated to eight neuropathologists, across eight institutions, who created “ground truth” annotations for Cellular Tumor (CT), Geographic Necrosis, Cortical Infiltration, Pseudopalisading Necrosis (PN), Microvascular Proliferation, and Penetration into White Matter (PWM). Comprehensive WSI curation for elimination of artifactual content and follow up partitioning resulted in approximately 300,000 data samples/patches. FINDINGS Inter-observer variability assessment highlighted difficulties in establishing a “gold standard”. The least annotated sub-regions (PWM and PN) were the most challenging to the participating methods, whereas all methods achieved their highest accuracy in the most annotated sub-region (CT). The highest average performance across sub-regions was obtained by a foundation model-based method. However, this top-ranked solution achieved an F1 score of 0.51 (Accuracy=0.65, Sensitivity=0.56, Specificity=0.93). CONCLUSIONS Our findings suggest that achieving state-of-the-art performance, in automatically identifying clinically-relevant glioblastoma sub-regions, remains an unsolved research problem. Analysis of the ground-truth annotations underscores the critical need for more precisely defined and neuropathologically standardized annotation protocol. Current AI algorithms are facing difficulties in addressing glioblastoma’s heterogeneous histologic landscape in the absence of large, comprehensively, and consistently annotated data. Building upon these findings, and towards developing more accurate AI algorithms, the 2025 iteration of the BraTS-Path challenge is currently on-going by leveraging two million data samples, aiming to enhance our disease understanding and improve diagnostic accuracy, ultimately contributing to improved patient outcomes.
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system
Baum, Laura Van Metre , Soulos, Pamela R. , Ruddy, Kathryn J. , Lerro, Catherine C. , Graham, David J. , Rivera, Donna R. , Liberatore, Mark, Jairam, Vikram , Gross, Cary P. , Park, Henry S. , Ruddy, Kathryn J , Leapman, Michael S , Gross, Cary P , Park, Henry S , KC, Madhav , Jeffery, Molly Moore , Lee, Hana , Leapman, Michael , Dinan, Michaela A.

Mayo Clinic

Cancer | September 22, 2025 | Volume: 131 | Issue: 19 | Pages: No page available

10.1002/cncr.70027 | PMID 40977160 Get It

Abstract Background Opioid stewardship policies could adversely affect pain management for patients with cancer. Yet patients with cancer are also at risk for opioid‐related harms. This study sought to determine trends in opioid prescribing by clinical stratum and pain for patients with cancer from 2016 to 2020. Methods A retrospective study was conducted of opioid‐naive adults with newly diagnosed cancer from 2016 to 2020 ( N = 10,232) in a large Connecticut health system. Logistic regression was used to calculate changes in the predicted probability of opioid prescribing from 2016 to 2020. Two subpopulations were examined: patients treated surgically ( n = 4405) and patients with metastatic cancer ( n = 2158). Flowsheet pain scores for patients with metastatic cancer were used to stratify by no pain (all scores, 0) versus any pain. The main outcomes were new (≥1 prescription in the 0–6 months after diagnosis) and additional (0–6 and 7–9 months) opioid prescriptions. Results A decline was observed in the predicted probability of new (71.1% to 64.6%; p < .001) and additional prescribing (27.2% to 24.2%; p = .07 [not significant]) declined. Among surgical patients, the predicted probability of new opioid prescribing fell (96.0% to 88.6%; p < .001), whereas additional prescribing was stable (13%). For patients with metastatic cancer with pain, new opioid prescribing was stable (56%). For those reporting no pain, the predicted probability of new opioid prescribing declined from 61.6% to 36.1% ( p < .001). Conclusions In the context of widespread policy changes, this study showed a modest decline in new and additional opioid prescribing for patients with cancer. In metastatic cancer, prescribing remained stable for patients reporting pain and declined steeply for those reporting no pain.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Avet‐Loiseau, Hervé , Davies, Faith E. , Samur, Mehmet , Corre, Jill , D’Agostino, Mattia , Kaiser, Martin , Raab, Marc S. , Weinhold, Niels , Gutiérrez, Norma C. , Paiva, Bruno , Walker, Brian A. , Bustoros, Mark , Stewart, A. Keith , Hillengaß, Jens , Martínez‐López, Joaquín , Sperling, Adam S. , Dhodapkar, Madhav V. , Spencer, Andrew , Parekh, Samir , Sonneveld, Pieter , Bergsagel, P. Leif , Orlowski, Robert Z. , Mateos, María‐Victoria , Kumar, Shaji , Munshi, Nikhil C. , Martinez-Lopez, Joaquin , Bergsagel, P. Leif , Samur, Mehmet K , Kaiser, Martin F , Weisel, Katja C , Maura, Francesco , Walker, Brian A , Bustoros, Mark , Stewart, A Keith , Usmani, Saad , Hillengass, Jens , Chng, Wee Joo , Keats, Jonathan J , Martinez-Lopez, Joaquin , Sperling, Adam S , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur S , Bolli, Niccolo' , Ghobrial, Irene M , Dhodapkar, Madhav V , Jagannath, Sundar , Spencer, Andrew , Parekh, Samir , Bahlis, Nizar Jacques , Sonneveld, Pieter , Orlowski, Robert Z. , Mateos, María-Victoria , San-Miguel, Jesus , Anderson, Kenneth C , Moreau, Philippe , Kumar, Shaji K , Munshi, Nikhil C , Raab, Marc S , Martinez-Lopez, Joaquin , Paiva, Bruno , Davies, Faith E , Corre, Jill , Mattia, D'Agostino , Neri, Paola , Maura, Francesco , Usmani, Saad Z. , Chng, Wee Joo , Keats, Jonathan J. , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur , Cavo, Michèle , Bolli, Niccolò , Ghobrial, Irene M. , Jagannath, Sundar , Lonial, Sagar , Morgan, Gareth J. , Rajkumar, S. Vincent , Miguel, Jesús F. San , Anderson, Kenneth C. , Moreau, Philippe , Prósper, Felipe

Mayo Clinic

Journal of Clinical Oncology | June 9, 2025 | Volume: 43 | Issue: 24 | Pages: 2739-2751

10.1200/jco-24-01893 | PMID 40489728 Get It

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).
Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myeloma
Ohlstrom, Denis , Pilcher, William , Michaud, Marina E. , Acharya, Chaitanya R. , Gonzalez‐Kozlova, Edgar , Jayasinghe, Reyka G. , Ferguson, Katherine E., Mumme, Hope , Nanda, Shivani , Mantrala, Sowmitri Karthikeya , Karagkouni, Dimitra , Pabustan, Nick , Santos, Junia Vieira Dos , Gout, Alex, Kourelis, Taxiarchis , Vij, Ravi , Dhodapkar, Madhav V. , Avigan, David , Kumar, Shaji , Ding, Li, Gnjatic, Sacha , Gnjatic, Sacha , Jayasinghe, Reyka G , Pilcher, William , Ohlstrom, Denis J , Acharya, Chaitanya , Mumme, Hope L , Satpathy, Sarthak , Ferguson, Katherine E., Song, Yizhe , Schulman, Jessica , Sherbenou, Daniel W , Keats, Jonathan J. , Foltz, Steven , Lagana, Alessandro , Cho, Hearn Jay , Baughn, Linda B. , Nooka, Ajay K. , Lonial, Sagar , Samur, Mehmet , Vlachos, Ioannis S. , Mulligan, George , Bhasin, Manoj K

Mayo Clinic

No container title available | June 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.27.656392 Get It

Abstract Multiple myeloma (MM) is an incurable malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune factors driving treatment response and resistance, we conducted multi-omics profiling including CD138 neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138 pos bulk RNA and whole-genome sequencing from 209 samples. Longitudinal analyses revealed that interferon gamma signaling impairs T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e -4 ). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell genes in monocytes, and T cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression. Statement of Significance Longitudinal profiling of multiple myeloma and the immune microenvironment revealed dynamic immune-tumor interactions across the disease course. Dysfunctional CD8⁺ T cells limited memory formation post-transplant, while naïve B recovery associated with sustained treatment response. At progression, cancer-testis antigen expression associated with immunosuppression, revealing novel mechanisms of immune escape.
Frailty Prevalence And Evaluation Of The FRAIL Scale Questionnaire In Patients with Inflammatory Bowel Disease
Elmer, Joshua, Eskarous, Hany , Ahuja, S. , Changela, Madhav , Stoltzfus, Jill, Schneider, Yecheskel , Bahirwani, Janak Tarun , Dahiya, Dushyant Singh

Mayo Clinic

No container title available | January 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5815707/v1 Get It

Abstract Background Inflammatory bowel disease (IBD) predisposes individuals to frailty, linked with adverse outcomes. While the Fried Frailty Index (FFI) is a well-established phenotypic tool to assess frailty, its administration is cumbersome. The FRAIL scale, simpler but not widely used in IBD patients, presents an alternative. We aimed to assess the prevalence of frailty and compare the FRAIL scale with the FFI. Methods Two hundred and nine confirmed IBD patients underwent assessment using both the FFI and the FRAIL scale. Patients were categorized as non-frail, pre-frail, or frail. Pearson coefficients evaluated correlation, and unadjusted analyses assessed frailty risk factors. ROC curve analysis evaluated the FRAIL scale. Results Among participants (53.5% female, median age 44), 37% were non-frail, 50% pre-frail, and 13% frail. The FRAIL scale exhibited strong correlation with the FFI for all three categories. Age showed no significant association with frailty. Frail individuals displayed higher inflammatory markers and more severe clinical disease, with frailty more prevalent in UC than CD patients. Frail individuals also exhibited lower hemoglobin, creatinine, and albumin levels. Conclusion Frailty and pre-frailty are prevalent in the IBD population, not necessarily linked with older age. The FRAIL scale demonstrated excellent correlation with the FFI, offering a practical tool for identifying frailty in IBD without physical measurements. Future studies should explore multivariable models incorporating frailty risk factors and interventions to mitigate adverse outcomes in the IBD population.
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up
Paul, Barry, Dhodapkar, Madhav V. , Alsina, Melissa , Vij, Ravi , Leleu, Xavier , Egan, Daniel , Truppel-Hartmann, Anna, Basudhar, Debashree, Thompson, Ethan, Eliason, Laurie , Park, Soyun, Tran, Sinhan, Chaudhry, Maria, Patel, Krina K. , Berdeja, Jesús G. , Richard, Shambavi , Bergsagel, P. Leif , Reshef, Ran , Usmani, Saad Z. , Wu, Fan , Siegel, David S.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3388-3388

10.1182/blood-2024-200829 Get It

Introduction Induction therapy (Tx) followed by ASCT and lenalidomide (LEN) maintenance is the standard of care in transplant-eligible pts with NDMM. Pts who have suboptimal response after front-line ASCT, however, have an increased risk of progression or death. Ide-cel demonstrated significantly improved median progression-free survival (PFS) and overall response rate (ORR) vs standard regimens in KarMMa-3 in pts with early-line triple-class-exposed relapsed and refractory multiple myeloma (MM). KarMMa-2 (NCT03601078) is a multicohort, phase 2, multicenter trial evaluating the efficacy and safety of ide-cel in several MM disease settings; cohort 2c includes pts with NDMM who achieved &lt; very good partial response (VGPR) after front-line ASCT. An extended follow-up analysis (median follow-up of 39.4 months) of cohort 2c was presented at ASH 2023 (Dhodapkar M, et al. ASH 2023; P2101). Here, we report results with 55.4 months of median follow-up and additional data on pts who received LEN maintenance at the investigator's discretion. Methods Adult pts with NDMM who received ≥ 3 cycles of induction Tx (proteasome inhibitor, immunomodulatory agent, dexamethasone), and had &lt; VGPR 70-110 days after ASCT (single/tandem) were eligible. Pts received a single ide-cel infusion (150-450 × 106 chimeric antigen receptor-positive T cells) and could receive maintenance Tx post-infusion at investigator discretion. The primary endpoint was complete response rate (CRR); secondary endpoints included ORR, duration of response (DOR), PFS, overall survival (OS), safety, cellular kinetics, and patient-reported outcomes on health-related quality of life (HRQoL). Minimal residual disease (MRD) negativity (sensitivity, 10-5), an exploratory endpoint, is also reported. Results At data cutoff (June 28, 2024), with a median follow-up of 55.4 (range, 51.4-59.5) months, all 31 pts treated with ide-cel were alive; 28 (90.3%) remained in follow-up and 3 (9.7%) discontinued due to disease progression or withdrawal by pt. Eight pts received LEN maintenance after ide-cel at the investigator's discretion. Among all 31 ide-cel-treated pts, CRR and ORR were 80.6% and 87.1%, respectively. Among the 8 pts who received LEN maintenance, CRR and ORR were 75.0% and 100.0%, respectively. Median DOR, PFS, and OS were not reached; 36-month event-free rates were 81.5%, 76.8%, and 100.0%, respectively. Of the 8 pts who received LEN maintenance after ide-cel infusion, none experienced disease progression. At 36 months, MRD negativity was confirmed in 12/18 (66.7%) evaluable pts; all 12 achieved ≥ CR. Since last data cutoff, 1 pt with MRD-negative MM changed to MRD-positive at 36 months, and 1 pt who had previously achieved MRD negativity was indeterminate at 36 months. Among the 6 evaluable pts who received LEN maintenance, 3/6 (50.0%) achieved MRD negativity at 36 months. There were no new safety signals nor reports of parkinsonism or Guillain-Barré syndrome since the previous data cutoff. In the 8 pts who received LEN maintenance, 6 (75.0%) experienced grade 3/4 AE, most commonly neutropenia, and 1 (12.5%) experienced grade 3/4 infection on or after LEN maintenance. All 8 pts were still receiving LEN at data cutoff. Robust CAR+ T cell expansion was observed in 31 pts, with higher expansion in pts with ≥ CR vs &lt; CR. Following ide-cel treatment, HRQoL improved and disease symptoms were stable over time (assessed by European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Core Questionnaire and EORTC Quality of Life Multiple Myeloma Module 20 Questionnaire). More than 75% of pts had improved or stable global health status/QoL by month 3. Conclusions With extended follow-up, ide-cel continued to demonstrate deep, durable responses in pts with &lt; VGPR to front-line ASCT. No new safety signals were observed and no deaths were reported. Data in a small group of pts in cohort 2c showed that ide-cel followed by LEN maintenance extended disease control. Pts who received LEN maintenance did not experience disease progression regardless of MRD status. Stable or improved HRQoL was observed after ide-cel treatment. Overall, ide-cel continued to show a favorable clinical benefit-risk profile in NDMM after ASCT. The phase 3 KarMMa-9 study (NCT06045806), currently recruiting, will compare ide-cel followed by LEN maintenance vs LEN maintenance alone in pts with NDMM after suboptimal response to ASCT.